<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354339</url>
  </required_header>
  <id_info>
    <org_study_id>MS-IGABONENSIS</org_study_id>
    <nct_id>NCT02354339</nct_id>
  </id_info>
  <brief_title>Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity</brief_title>
  <official_title>Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The metabolic syndrome is a high prevalence disease worldwide. About a quarter of the adult&#xD;
      population suffers from the disease and predispose the onset of diseases like cardiovascular&#xD;
      disease and diabetes mellitus type 2.&#xD;
&#xD;
      The first line of treatment for metabolic syndrome is diet and exercise but patients have a&#xD;
      low attachment to the treatment, so pharmacologic therapy is required. There is no a single&#xD;
      drug that could help to the treatment of all metabolic syndrome components.&#xD;
&#xD;
      Irvingia gabonensis, better known as African mango, is widely consumed in central and western&#xD;
      Africa, mainly the fruit and seeds. Besides being part of the diet of African the seeds have&#xD;
      been used for the treatment of diseases such as dysentery, diabetes and as an analgesic.&#xD;
&#xD;
      Resent investigations have demonstrated that an extract of African mango seeds induce&#xD;
      significantly weight loss in subjects with obesity, and also improves some biochemical&#xD;
      parameters such as glucose and the lipid profile.&#xD;
&#xD;
      The aim of this study is to evaluate the effect of Irvingia gabonensis on metabolic syndrome,&#xD;
      insulin secretion and insulin sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled, clinical trial is going to be carried out in&#xD;
      24 patients of both sexes aged between 30 and 60 years, with diagnosis of metabolic syndrome&#xD;
      according to the modified International Diabetes Federation (IDF) criteria (without diabetes&#xD;
      and without previous treatment for metabolic syndrome components).&#xD;
&#xD;
      The patients will be assigned randomly into two groups of 12 patients each. The patients will&#xD;
      receive 150 mg of Irvingia gabonensis before breakfast and dinner (300 mg per day) or placebo&#xD;
      during 12 weeks.&#xD;
&#xD;
      Waist circumference, triglycerides, high density lipoproteins (HDL-c) and blood pressure will&#xD;
      be evaluated before and after intervention in both groups.&#xD;
&#xD;
      First phase of insulin secretion (Stumvoll index), total insulin secretion (Insulinogenic&#xD;
      index) and Insulin sensitivity (Matsuda index) will be calculated from the concentration of&#xD;
      glucose and insulin obtained from an Oral Glucose Tolerance Test.&#xD;
&#xD;
      Data from statistical analysis will be presented through measures of central tendency and&#xD;
      dispersion, mean and standard deviation for quantitative variables and frequencies and&#xD;
      percentages for qualitative variables. Qualitative variables will be analyzed by X2. The&#xD;
      inter group differences will be analyzed through Mann-Whitney U test and Wilcoxon Test for&#xD;
      intra-group differences. Statistical significance will be considered with a p&lt;0.05.&#xD;
&#xD;
      This protocol was approved by a local ethics committee and written informed consent will be&#xD;
      obtained from all volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a study with two groups of patients with metabolic syndrome. One group received Irvingia Gabonensis and the other received placebo as control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Glucose Levels at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting glucose will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides Levels at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglycerides will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Density Lipoprotein (HDL-C) Levels at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The HDL-C will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Blood Pressure at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The systolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Blood Pressure at Week 12.</measure>
    <time_frame>Baseline. Week 12</time_frame>
    <description>The diastolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Waist Circumference at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The waist circumference will be evaluated at baseline and at week 12 with a flexible validated metric tape</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Phase of Insulin Secretion at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The first phase of insulin secretion will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Insulin Secretion at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total insulin secretion will be calculated at baseline and week 12 with the insulinogenic index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Insulin Sensitivity at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin sensitivity will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The body weight will be measured at baseline and week 12 with a bioimpedance balance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The body mass index will be calculated at baseline and week 12 with the Quetelet index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total cholesterol will be estimated bye standardized techniques at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoproteins (LDL-C) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The LDL-C will be calculated at baseline and week 12 with the Friedewald formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The aspartate aminotransferase will be determinated by standardized techniques at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The alanine aminotransferase will be determinated by standardized techniques at baseline and week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Creatinine levels will be measured at baseline and week 12 with standardized techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric Acid at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Uric acid levels will be measured at baseline and week 12 with standardized techniques</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Irvingia gabonensis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Irvingia gabonensis</intervention_name>
    <description>Intervention will be administered 30 minutes before meals</description>
    <arm_group_label>Irvingia gabonensis</arm_group_label>
    <other_name>African mango</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention will be administered 30 minutes before meals</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients both sexes&#xD;
&#xD;
          -  Age between 30 and 60 years&#xD;
&#xD;
          -  Metabolic syndrome according IDF modified criteria&#xD;
&#xD;
          -  Waist circumference: Men ≥90 cm, women ≥80 cm&#xD;
&#xD;
        And two of the following criteria:&#xD;
&#xD;
          -  HDL-C: Men ≤40 mg/dL, women ≤50 mg/dL&#xD;
&#xD;
          -  Fasting glucose ≥100 mg/dL&#xD;
&#xD;
          -  Triglycerides ≥150 mg/dL&#xD;
&#xD;
          -  Blood pressure ≥130/85 mmHg&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy&#xD;
&#xD;
          -  Women under lactation and/or puerperium&#xD;
&#xD;
          -  Known hypersensibility to Irvingia gabonensis&#xD;
&#xD;
          -  Physical impossibility for taking pills&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, heart or thyroid disease&#xD;
&#xD;
          -  Previous treatment for the metabolic syndrome components&#xD;
&#xD;
          -  Body mass index ≥ 39.9 kg/m2&#xD;
&#xD;
          -  Fasting glucose ≥126 mg/dL&#xD;
&#xD;
          -  Triglycerides ≥ 500 mg/dL&#xD;
&#xD;
          -  Total cholesterol ≥ 240 mg/dL&#xD;
&#xD;
          -  LDL-C ≥190 mg/dL&#xD;
&#xD;
          -  Blood pressure ≥140/90 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Terapéutica Experimental y Clínica</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <results_first_submitted>August 23, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Researcher Professor</investigator_title>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Irvingia gabonensis</keyword>
  <keyword>African mango</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Irvingia Gabonensis</title>
          <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Irvingia Gabonensis</title>
          <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="7.1"/>
                    <measurement group_id="B2" value="47.8" spread="6.1"/>
                    <measurement group_id="B3" value="47.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.04" spread="0.7"/>
                    <measurement group_id="B2" value="5.9" spread="0.5"/>
                    <measurement group_id="B3" value="5.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="1.2"/>
                    <measurement group_id="B2" value="2.2" spread="0.6"/>
                    <measurement group_id="B3" value="2.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoproteins (HDL-c)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" spread="0.3"/>
                    <measurement group_id="B2" value="1.6" spread="0.4"/>
                    <measurement group_id="B3" value="1.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125.3" spread="13.0"/>
                    <measurement group_id="B2" value="128.4" spread="8.5"/>
                    <measurement group_id="B3" value="126.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.9" spread="7.4"/>
                    <measurement group_id="B2" value="82.7" spread="8.0"/>
                    <measurement group_id="B3" value="80.8" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.0" spread="8.0"/>
                    <measurement group_id="B2" value="96.9" spread="9.0"/>
                    <measurement group_id="B3" value="95.5" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>First phase of insulin secretion</title>
          <description>Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1306" spread="1500"/>
                    <measurement group_id="B2" value="2036" spread="2115"/>
                    <measurement group_id="B3" value="1670.9" spread="1831.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total insulin secretion</title>
          <description>The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" spread="0.2"/>
                    <measurement group_id="B2" value="0.8" spread="0.5"/>
                    <measurement group_id="B3" value="0.63" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total insulin sensitivity</title>
          <description>Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="1.8"/>
                    <measurement group_id="B2" value="1.9" spread="0.9"/>
                    <measurement group_id="B3" value="2.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.6" spread="13.0"/>
                    <measurement group_id="B2" value="78.5" spread="9.2"/>
                    <measurement group_id="B3" value="79.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="4.4"/>
                    <measurement group_id="B2" value="31.2" spread="3.9"/>
                    <measurement group_id="B3" value="31.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="0.6"/>
                    <measurement group_id="B2" value="5.4" spread="0.7"/>
                    <measurement group_id="B3" value="5.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoproteins (LDL-c)</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="1.0"/>
                    <measurement group_id="B2" value="3.0" spread="0.9"/>
                    <measurement group_id="B3" value="3.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase (ALT)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="12.2"/>
                    <measurement group_id="B2" value="33.8" spread="27.1"/>
                    <measurement group_id="B3" value="30.4" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate aminotransferase (AST)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="16.7"/>
                    <measurement group_id="B2" value="33.9" spread="20.4"/>
                    <measurement group_id="B3" value="30.7" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.7" spread="17.7"/>
                    <measurement group_id="B2" value="70.7" spread="17.7"/>
                    <measurement group_id="B3" value="70.7" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Uric acid</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374.7" spread="148.7"/>
                    <measurement group_id="B2" value="392.6" spread="59.5"/>
                    <measurement group_id="B3" value="383.7" spread="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Glucose Levels at Week 12</title>
        <description>Fasting glucose will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose Levels at Week 12</title>
          <description>Fasting glucose will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.7"/>
                    <measurement group_id="O2" value="5.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of fasting glucose on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.240</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of fasting glucose on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.850</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides Levels at Week 12</title>
        <description>Triglycerides will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides Levels at Week 12</title>
          <description>Triglycerides will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.1"/>
                    <measurement group_id="O2" value="2.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of triglycerides on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of triglycerides on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.391</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High Density Lipoprotein (HDL-C) Levels at Week 12</title>
        <description>The HDL-C will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein (HDL-C) Levels at Week 12</title>
          <description>The HDL-C will be evaluated at baseline and week 12 with enzymatic-colorimetric techniques</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.4"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of HDL-c on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.206</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of HDL-c on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.721</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure at Week 12</title>
        <description>The systolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure at Week 12</title>
          <description>The systolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.5" spread="10.6"/>
                    <measurement group_id="O2" value="126.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of systolic blood pressure on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.371</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of systolic blood pressure on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.238</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diastolic Blood Pressure at Week 12.</title>
        <description>The diastolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer</description>
        <time_frame>Baseline. Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure at Week 12.</title>
          <description>The diastolic and blood pressure will be evaluated at baseline and at week 12 with a digital sphygmomanometer</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="7.3"/>
                    <measurement group_id="O2" value="81.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of diastolic blood pressure on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.452</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of diastolic blood pressure on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.801</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Waist Circumference at Week 12</title>
        <description>The waist circumference will be evaluated at baseline and at week 12 with a flexible validated metric tape</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference at Week 12</title>
          <description>The waist circumference will be evaluated at baseline and at week 12 with a flexible validated metric tape</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" spread="8.2"/>
                    <measurement group_id="O2" value="97.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of waist circumference on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of waist circumference on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.752</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>First Phase of Insulin Secretion at Week 12</title>
        <description>The first phase of insulin secretion will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>First Phase of Insulin Secretion at Week 12</title>
          <description>The first phase of insulin secretion will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.&#xD;
First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the first phase of insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1382" spread="1119"/>
                    <measurement group_id="O2" value="1690" spread="1070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of first phase of insulin secretion on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.791</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of first phase of insulin secretion on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.910</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Insulin Secretion at Week 12</title>
        <description>Total insulin secretion will be calculated at baseline and week 12 with the insulinogenic index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Secretion at Week 12</title>
          <description>Total insulin secretion will be calculated at baseline and week 12 with the insulinogenic index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.&#xD;
Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin/ΔABC glucose), the entered values reflect the total insulin secretion</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.20"/>
                    <measurement group_id="O2" value="0.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total insulin secretion on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.458</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total insulin secretion on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Insulin Sensitivity at Week 12</title>
        <description>Insulin sensitivity will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Total Insulin Sensitivity at Week 12</title>
          <description>Insulin sensitivity will be calculated at baseline and week 12 with the stumvoll index from concentrations of glucose and insulin obtained of an oral glucose tolerance test.&#xD;
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.7"/>
                    <measurement group_id="O2" value="1.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of insulin sensitivity on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.470</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of insulin sensitivity on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.807</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight at Week 12</title>
        <description>The body weight will be measured at baseline and week 12 with a bioimpedance balance.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight at Week 12</title>
          <description>The body weight will be measured at baseline and week 12 with a bioimpedance balance.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" spread="12.8"/>
                    <measurement group_id="O2" value="79.0" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of body weight on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.604</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of body weight on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.350</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index at Week 12</title>
        <description>The body mass index will be calculated at baseline and week 12 with the Quetelet index</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index at Week 12</title>
          <description>The body mass index will be calculated at baseline and week 12 with the Quetelet index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="4.3"/>
                    <measurement group_id="O2" value="31.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of BMI on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.727</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of BMI on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.229</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol at Week 12</title>
        <description>Total cholesterol will be estimated bye standardized techniques at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol at Week 12</title>
          <description>Total cholesterol will be estimated bye standardized techniques at baseline and week 12</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="0.9"/>
                    <measurement group_id="O2" value="5.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total cholesterol on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.151</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of total cholesterol on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.955</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoproteins (LDL-C) at Week 12</title>
        <description>The LDL-C will be calculated at baseline and week 12 with the Friedewald formula</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoproteins (LDL-C) at Week 12</title>
          <description>The LDL-C will be calculated at baseline and week 12 with the Friedewald formula</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.9"/>
                    <measurement group_id="O2" value="2.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of LDL-c on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.350</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of LDL-c on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.470</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase at Week 12</title>
        <description>The aspartate aminotransferase will be determinated by standardized techniques at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase at Week 12</title>
          <description>The aspartate aminotransferase will be determinated by standardized techniques at baseline and week 12</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="15.8"/>
                    <measurement group_id="O2" value="27.8" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of AST on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.910</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of AST on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.436</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase at Week 12</title>
        <description>The alanine aminotransferase will be determinated by standardized techniques at baseline and week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase at Week 12</title>
          <description>The alanine aminotransferase will be determinated by standardized techniques at baseline and week 12</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="14.1"/>
                    <measurement group_id="O2" value="31.9" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of ALT on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.989</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of ALT on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.949</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine at Week 12</title>
        <description>Creatinine levels will be measured at baseline and week 12 with standardized techniques</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine at Week 12</title>
          <description>Creatinine levels will be measured at baseline and week 12 with standardized techniques</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="17.7"/>
                    <measurement group_id="O2" value="70.7" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of creatinine on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of creatinine on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.401</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uric Acid at Week 12</title>
        <description>Uric acid levels will be measured at baseline and week 12 with standardized techniques</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Irvingia Gabonensis</title>
            <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
          </group>
        </group_list>
        <measure>
          <title>Uric Acid at Week 12</title>
          <description>Uric acid levels will be measured at baseline and week 12 with standardized techniques</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.0" spread="53.5"/>
                    <measurement group_id="O2" value="404.5" spread="119.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of uric acid on Irvingia gabonensis group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.910</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results showed in this section are the result of the differences between baseline and final values of uric acid on placebo group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.791</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 12 weeks of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Irvingia Gabonensis</title>
          <description>Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Irvingia gabonensis: Intervention will be administered 30 minutes before meals</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks&#xD;
Placebo: Intervention will be administered 30 minutes before meals</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DR. MANUEL GONZALEZ ORTIZ</name_or_title>
      <organization>INSTITUTO DE TERAPEUTICA EXPERIMENTAL Y CLINICA, UNIVERSITY OF GUADALAJARA</organization>
      <phone>+52 3310585200 ext 34212</phone>
      <email>uice@prodigy.net.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

